RxDoctor Payments Data

Suzanne Manzi

Physical Medicine & Rehabilitation · Houston, TXNPI 1003051731

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Stimwave Technologies Incorporated at 54.4% of the total. Reporting peaked in 2019 at $51,033 and has fallen 90.1% since, to $5,064 in 2025. Among physical medicine & rehabilitation clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$143,297in general payments, 2019–2025

Across 1,048 payments — averaging $136.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stimwave Technologies Incorporated$78K
  • Boston Scientific$10K
  • Abbott$9K
  • Avanos Medical$7K
  • Medtronic$7K
  • Eli Lilly$6K
  • plus $27K from 54 others

What the payments were for

  • Consulting fees$71,35050%
  • Speaking & faculty fees$11,9068%
  • Travel & lodging$19,12413%
  • Food & beverage$36,71126%
  • Education$1,0001%
  • Gifts$2390%
  • Entertainment$2,9662%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stimwave Technologies Incorporated127$78,005
Boston Scientific93$10,007
Abbott134$9,391
Avanos Medical8$6,823
Medtronic(2 entities)153$6,633
Eli Lilly7$5,524
Biotronik NRO, Inc.11$3,522
Stratus Medical, LLC8$3,251
Curonix LLC20$2,923
MML US, Inc.50$2,533
Nevro Corp.33$1,842
Vertos Medical, Inc.15$980
AbbVie(2 entities)42$943
Relievant Medsystems, Inc.19$850
Collegium Pharmaceutical, Inc.50$811
Aurora Spine, Inc.1$750
Saluda Medical Americas, Inc.13$744
Stryker6$723
SPR Therapeutics, Inc7$602
Scilex Pharmaceuticals Inc.25$452
Novo Nordisk8$380
Amgen(2 entities)10$375
VGI Medical, LLC2$353
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$323
Spinal Simplicity, LLC3$270
Biodelivery Sciences International, Inc.16$257
Pfizer12$248
Redhill Biopharma Inc.14$232
Teva Pharmaceuticals USA, Inc.9$223
Globus Medical3$205
Vertiflex, Inc.4$199
Tersera Therapeutics LLC7$194
Merz Pharmaceuticals, LLC7$186
Spinefrontier, Inc.2$183
Lilly USA, LLC10$162
Merz North America, Inc.7$161
Sentynl Therapeutics, Inc.15$160
Nalu Medical, Inc.3$134
Rhythm Pharmaceuticals, Inc.1$125
Dexcom, Inc.1$118
Lundbeck LLC5$113
Biohaven Pharmaceutical Holding Company Ltd.1$112
Pacira Therapeutics, Inc.6$111
Eisai Inc.5$108
MDD US Operations, LLC7$108
Pacira Pharmaceuticals Incorporated5$103
Painteq LLC4$97
Bioventus LLC4$89
Novartis5$89
IBSA Pharma Inc.3$55
GRT US Holding, Inc.2$43
Johnson & Johnson3$40
Idorsia Pharmaceuticals US Inc2$39
Si-bone, Inc.2$38
Arbor Pharmaceuticals, Inc.2$34
Biohaven Pharmaceuticals, Inc.2$31
Virtus Pharmaceuticals LLC2$31
Baxter Healthcare1$30
Kyowa Kirin, Inc.1$28
Almatica Pharma LLC1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$143,297 in reported general payments places this provider in the 95th percentile of 651 physical medicine & rehabilitation providers in Texas.

See all physical medicine & rehabilitation providers in Texas

Medicare billing

Part B allowed, 2024
$223,132
Medicare patients
188
Services billed
4,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl96$82,601
Xtampza ErOxycodone Myristate22$19,782
MovantikNaloxegol Oxalate14$9,384
DayvigoLemborexant12$3,955
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen122$3,329
Morphine Sulfate ErMorphine Sulfate93$3,160
Gabapentin99$1,858
Pregabalin61$1,406
Fentanyl13$1,247
Tramadol Hcl62$1,035
Methadone Hcl47$765
Cyclobenzaprine Hcl34$643
Lidocaine11$639
Tizanidine Hcl35$638
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$811$102,383118 claims
Redhill Biopharma Inc.Movantik$232$9,38414 claims
Eisai Inc.Dayvigo$108$3,95512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 651 physical medicine & rehabilitation providers in Texas.

Other physical medicine & rehabilitation in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →